ReShape Lifesciences Inc (OQ:RSLS)

Business Focus: Advanced Medical Equipment & Technology

Apr 01, 2024 04:05 pm ET
ReShape Lifesciences® Reports Year Ended December 31, 2023 Financial Results and Provides Corporate Update
ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today reported financial results for the fourth quarter and fiscal year ended December 31, 2023 and provided a corporate...
Mar 28, 2024 08:31 am ET
ReShape Lifesciences® Receives Notice of Allowance for Additional U.S. Patent Related to an Intragastric Balloon System
ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that the company has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent...
Mar 04, 2024 08:31 am ET
ReShape Lifesciences® Provides Update on 2024 Cost Reduction Plan and Reorganization to Prioritize Commercialization of Lap-Band® 2.0 FLEX
ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced a 2024 cost reduction plan and reorganization to prioritize the commercialization of the company’s next generation,...
Feb 22, 2024 08:31 am ET
ReShape Lifesciences® Announces First Surgeries Utilizing Next-Generation Lap-Band® 2.0 FLEX
ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that Adam Smith, D.O., Bariatric Surgery Specialist and Chief Executive Officer of Ultimate Bariatrics in Dallas,...
Jan 24, 2024 08:31 am ET
ReShape Lifesciences® Conducts Bariatric Fellows Training for its Lap-Band® System, Highlighting the Next-Generation Lap-Band® 2.0 FLEX
ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that bariatric surgical fellows from the University of Texas Health Center in Houston, Texas were trained on Friday,...
Dec 20, 2023 08:31 am ET
ReShape Lifesciences® Engages Maxim Group LLC To Identify Strategic M&A Partnership Alternatives
ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that it has engaged Maxim Group LLC, to act as the Company’s exclusive financial advisor to identify potential...
Dec 12, 2023 04:05 pm ET
ReShape Lifesciences® Receives FDA PMA Supplement Approval for its Next-Generation Lap-Band® 2.0 FLEX
ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that the U.S. Food and Drug Administration (FDA) has granted approval of a PMA supplement for the company’s next...
Nov 21, 2023 08:06 am ET
ReShape Lifesciences® Enters into Warrant Exercise Transaction for $1.2 Million in Gross Proceeds
ReShape Lifesciences, Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, announced today that it has entered into a warrant exercise agreement with an existing accredited investor to exercise...
Nov 08, 2023 04:05 pm ET
ReShape Lifesciences® Reports Third Quarter Ended September 30, 2023 Financial Results and 2024 Cost Reduction Plan
ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today reported financial results for the third quarter ended September 30, 2023 and provided a corporate strategic update....
Nov 06, 2023 08:31 am ET
ReShape Lifesciences® to Announce Financial Results for the Third Quarter Ended September 30, 2023 and Provide Corporate Update
ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that it will report its financial results for the third quarter ended September 30, 2023, including a corporate...
Sep 29, 2023 12:30 pm ET
ReShape Lifesciences® Announces Pricing of $3.0 Million Public Offering
ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced the pricing of its public offering of 9,100,000 units, with each unit consisting of one share of common stock (or...
Sep 22, 2023 08:31 am ET
ReShape Lifesciences® Announces Participation in the LD Micro Main Event XVI
ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that Paul F. Hickey, President and Chief Executive Officer, and Tom Stankovich, Chief Financial Officer, will...
Sep 21, 2023 08:31 am ET
ReShape Lifesciences® Signs Exclusive License Agreement With Biorad Medisys for Obalon® Gastric Balloon System
ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced the signing of an exclusive, royalty-bearing license agreement with Biorad Medysis, Pvt. Ltd. (Biorad) to...
Sep 19, 2023 08:31 am ET
ReShape Lifesciences® Significantly Strengthens Patent Portfolio Related to its Obalon® Balloon System
ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that the company has significantly strengthened the patent portfolio related to its Obalon® Balloon System....
Sep 14, 2023 08:31 am ET
ReShape Lifesciences® Receives NIH SBIR Grant to Further Develop Proprietary Diabetes Bloc-Stim Neuromodulation™ Device
ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that the Company was awarded a $331,541 Small Business Innovation Research (SBIR) grant for the development of...
Aug 07, 2023 04:05 pm ET
ReShape Lifesciences® Reports Second Quarter Ended June 30, 2023 Financial Results and Provides Corporate Update
ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today reported financial results for the second quarter ended June 30, 2023 and provided a corporate strategic update....
Aug 03, 2023 04:05 pm ET
ReShape Lifesciences® to Announce Financial Results for the Second Quarter Ended June 30, 2023 and Provide Corporate Update
ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that it will report its financial results for the second quarter ended June 30, 2023, including a corporate...
Jun 29, 2023 08:31 am ET
ReShape Lifesciences® Signs Preferred Partner Agreement With Hive Medical for Lead Optimization Software
ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced the signing of a preferred partner agreement with Hive Medical (Hive). Hive’s software suite leverages AI,...
Jun 28, 2023 08:31 am ET
ReShape Lifesciences® Presents Data on its Proprietary Diabetes Bloc-Stim Neuromodulation™ Device at the ASMBS 2023 Annual Meeting
ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today presented data on its proprietary Diabetes Bloc-Stim Neuromodulation™ (DBSN™) device in an e-poster at the American...
Jun 26, 2023 04:05 pm ET
ReShape Lifesciences® Submits FDA PMA Supplement Application for the Next-Generation Lap-Band® 2.0
ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced the submission of a Premarket Approval (PMA) supplement application to the U.S. Food and Drug Administration (FDA)...
Jun 23, 2023 08:35 am ET
Life Science Investor Forum: Presentations Now Available for Online Viewing
Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from Life Science Investor Forum, held on June 22nd are now available for online viewing. REGISTER NOW AT: https://bit.ly/3NuvXOW...
Jun 20, 2023 10:58 am ET
Life Science Investor Forum Agenda Announced for June 22nd
Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the Life Science Investor Forum. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER...
Jun 14, 2023 08:31 am ET
ReShape Lifesciences® to Participate in Investor and Industry Conferences in June
ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced participation in the following investor and industry conferences in June: June 20-21: Maxim Virtual...
May 15, 2023 04:05 pm ET
ReShape Lifesciences® Reports First Quarter Ended March 31, 2023 Financial Results and Provides Corporate Update
ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today reported financial results for the first quarter ended March 31, 2023 and provided a corporate strategic update. First...
May 11, 2023 08:30 am ET
ReShape Lifesciences® to Announce Financial Results for the First Quarter Ended March 31, 2023 and Provide Corporate Update
ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that it will report its financial results for the first quarter ended March 31, 2023, including a corporate...
Apr 27, 2023 08:30 am ET
ReShape Lifesciences® to Present Data on its Proprietary Diabetes Bloc-Stim Neuromodulation™ Device at the Keystone Symposia on Type 2 Diabetes
ReShape Lifesciences™ (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced it will present data on its proprietary Diabetes Bloc-Stim Neuromodulation™ (DBSN™) device in a poster at the...
Apr 25, 2023 04:05 pm ET
ReShape Lifesciences® Reports Year Ended December 31, 2022 Financial Results and Provides Corporate Update
ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today reported financial results for the year ended December 31, 2022 and provided a corporate strategic update. Fourth Quarter...
Apr 20, 2023 08:30 am ET
ReShape Lifesciences Announces Pricing of $2.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market
ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase...
Apr 11, 2023 08:30 am ET
ReShape Lifesciences® Receives Notice of Allowance for U.S. Patent Related to its Obalon® Balloon System
ReShape Lifesciences™ (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that the company has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent...
Mar 28, 2023 09:50 pm ET
ReShape Lifesciences® To Delay Year Ended December 31, 2022 Earnings Release and Conference Call
ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that it will delay its year ended December 31, 2022 earnings release and conference call, previously scheduled...
Mar 23, 2023 08:30 am ET
ReShape Lifesciences Announces Formation of International Scientific Advisory Board
ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced the formation of a Scientific Advisory Board (SAB). Members include internationally recognized experts and...
Mar 22, 2023 08:30 am ET
ReShape Lifesciences® to Announce Financial Results for the Year Ended December 31, 2022, and Provide Corporate Update
ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that it will report its financial results for the year ended December 31, 2022, including a corporate update, on...
Mar 15, 2023 08:30 am ET
ReShape Lifesciences® to Present at the Q2 Virtual Investor Summit
ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that Paul F. Hickey, President and Chief Executive Officer, and Tom Stankovich, Chief Financial Officer, will...
Feb 08, 2023 12:07 pm ET
ReShape Lifesciences Announces Closing of Upsized $10.2 Million Underwritten Public Offering
ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced the closing of its upsized underwritten public offering of 1,275,000 units, with each unit consisting of one...
Feb 06, 2023 08:30 am ET
ReShape Lifesciences Announces Pricing of Upsized $10.2 Million Underwritten Public Offering
ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced the pricing of its upsized underwritten public offering of 1,275,000 units, with each unit consisting of one...
Dec 23, 2022 07:53 am ET
Thinking about buying stock in ReShape Lifesciences, Exicure, Blue Apron, Coherus Biosciences, or Icecure Medical?
NEW YORK, Dec. 23, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for RSLS, XCUR, APRN, CHRS, and ICCM.
Dec 22, 2022 08:30 am ET
ReShape Lifesciences Announces 1-for-50 Reverse Stock Split Effective as of Commencement of Trading on December 23, 2022
ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that its Board of Directors has declared a 1-for-50 reverse stock split of the company’s common stock, which...
Nov 14, 2022 07:30 am ET
ReShape Lifesciences™ Reports Third Quarter 2022 Financial Results and Provides Corporate Update
ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today reported financial and operating results for the third quarter ended September 30, 2022 and provided a corporate strategic...
Nov 08, 2022 09:28 am ET
ReShape Lifesciences Announces $750,000 Registered Direct Offering
ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that it has entered into a securities purchase agreement with a single institutional investor for the purchase...
Nov 07, 2022 01:22 pm ET
ReShape Lifesciences™ to Announce Financial Results for the Third Quarter Ended September 30, 2022, and Provide Corporate Update
ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that it will report its financial results for the third quarter ended September 30, 2022, including a corporate...
Nov 03, 2022 08:30 am ET
ReShape Lifesciences™ Presents Data on Proprietary Diabetes Bloc-Stim Neuromodulation™ Device at ObesityWeek®
ReShape Lifesciences™ (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced the presentation of data on its proprietary Diabetes Bloc-Stim Neuromodulation™ (DBSN™) device in an abstract at the...
Nov 02, 2022 09:11 am ET
ReShape Lifesciences to Present at the Q4 Investor Summit
ReShape Lifesciences™ (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that Paul F. Hickey, President and Chief Executive Officer, and Tom Stankovich, Chief Financial Officer, will...
Oct 31, 2022 08:30 am ET
ReShape Lifesciences™ Announces That the ASMBS and IFSO Have Issued Updated Guidelines on Indications for Metabolic and Bariatric Surgery, Including the Lap-Band®
ReShape Lifesciences™ (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that the American Society for Metabolic and Bariatric Surgery (ASMBS) and the International Federation for the...
Oct 25, 2022 08:30 am ET
ReShape Lifesciences™ Announces Publication of Data on Proprietary Diabetes Bloc-Stim Neuromodulation™ (DBSN™) System in Peer Reviewed, Frontiers in NeuroScience
ReShape Lifesciences™ (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that data on the Company’s proprietary Diabetes Bloc-Stim Neuromodulation™ (DBSN™) system has been published in the...
Oct 20, 2022 08:30 am ET
ReShape Lifesciences™ Announces Release of a Positive Consensus Statement on Lap-Band® Use and Lap-Band® Aftercare Management by the American Society of Metabolic and Bariatric Surgery (ASMBS)
ReShape Lifesciences™ (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that the American Society for Metabolic and Bariatric Surgery (ASMBS) has issued a Consensus Statement on Lap-Band®...
Sep 22, 2022 08:30 am ET
ReShape Lifesciences™ Awarded Phase I NIH SBIR Grant to Further Develop Proprietary Diabetes Bloc-Stim Neuromodulation™ Device
ReShape Lifesciences™ (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that the Company was awarded a $300,000 Small Business Innovation Research (SBIR) grant for the development of...
Sep 14, 2022 08:30 am ET
ReShape Lifesciences Announces Participation in the A.G.P Virtual MedTech Conference
ReShape Lifesciences™ (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that Paul F. Hickey, President and Chief Executive Officer and Tom Stankovich, Chief Financial Officer, will be...
Aug 23, 2022 08:30 am ET
ReShape Lifesciences Appoints Seasoned Sales and Marketing Executive, Nick Ansari, as Senior Vice President of Global Commercial Operations
ReShape Lifesciences™ (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that the company has appointed Nick Ansari as Senior Vice President of Global Commercial Operations, effective...
Aug 15, 2022 04:05 pm ET
ReShape Lifesciences™ Reports Second Quarter 2022 Financial Results and Provides Corporate Update
ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today reported financial and operating results for the second quarter ended June 30, 2022 and provided a corporate strategic...
Aug 10, 2022 04:29 pm ET
ReShape Lifesciences™ to Announce Financial Results for the Second Quarter Ended June 30, 2022 and Provide Corporate Update
ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that it will report its financial results for the second quarter ended June 30, 2022, including a corporate...
Aug 10, 2022 12:05 pm ET
ReShape Lifesciences™ Receives FDA 510(k) Clearance for the GIBI HD™ Calibration Tubes for use in Gastric and Bariatric Procedures
ReShape Lifesciences™ (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the disposable, Gastro Intestinal...
Jul 27, 2022 04:05 pm ET
ReShape Lifesciences Announces Appointment of Paul F. Hickey as President and Chief Executive Officer
ReShape Lifesciences™ (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that its Board of Directors has appointed Paul F. Hickey as President and Chief Executive Officer and as a member of...
Jun 17, 2022 08:30 am ET
ReShape Lifesciences Enters into Warrant Exercise Transaction for $2.5 Million in Gross Proceeds
ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, announced today that it has entered into a warrant exercise agreement with an existing accredited investor to exercise...
May 23, 2022 08:00 am ET
ReShape Lifesciences™ Reports First Quarter 2022 Financial Results and Provides Corporate Update
ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today reported financial and operating results for the first quarter ended March 31, 2022 and provided a corporate strategic...
May 19, 2022 08:30 am ET
ReShape Lifesciences™ Announces Vernon Vincent to be Recognized as the Distinguished Industry Partner at the ASMBS 2022 LEAD Gala and Awards
ReShape Lifesciences™ (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that Vernon “Vern” Vincent, the company’s Senior Director, Global Professional Education and Medical Affairs, will...
May 16, 2022 08:30 am ET
ReShape Lifesciences™ to Announce Financial Results for the First Quarter Ended March 31, 2022 and Provide Corporate Update
ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that it will report its financial results for the first quarter ended March 31, 2022, including a corporate...
Apr 26, 2022 08:30 am ET
ReShape Lifesciences to Present at the Q2 Investor Summit
ReShape Lifesciences™ (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that Bart Bandy, President and Chief Executive Officer, and Tom Stankovich, Chief Financial Officer, will present a...
Mar 28, 2022 04:05 pm ET
ReShape Lifesciences™ Reports Year Ended 2021 Financial and Operating Results and Provides Corporate Update
ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today reported financial and operating results for the year ended December 31, 2021 and provided a corporate strategic update....
Mar 24, 2022 08:30 am ET
ReShape Lifesciences™ Experiences Continued Momentum of Direct-to-Consumer Marketing Campaign for the Lap-Band®
ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced continued momentum in its national, direct-to-consumer (DTC) marketing campaign, culminating in substantial...
Mar 17, 2022 09:07 am ET
ReShape Lifesciences™ to Announce Financial Results for the Year Ended December 31, 2021 and Provide Corporate Update
ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that it will report its financial results for the year-ended December 31, 2021, including a corporate update, on...
Mar 09, 2022 08:30 am ET
ReShape Lifesciences to Participate in Investor Conferences in March
ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced participation in the following investor conferences in March: March 15-17: Oppenheimer 32nd Annual Virtual...
Jan 18, 2022 08:30 am ET
ReShape Lifesciences™ to Participate in the American Society for Metabolic and Bariatric Surgery’s (ASMBS) Leadership Academy and re-UNITED Meeting January 19-22, 2022 in Las Vegas
ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced its sponsorship of and participation in the American Society for Metabolic and Bariatric Surgery’s (ASMBS)...
Jan 13, 2022 08:30 am ET
ReShape Lifesciences Strengthens Leadership Team with Appointment of Michael Bordainick as Senior Vice President, Commercial Operations
ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced the appointment of Michael Bordainick as its Senior Vice President, Commercial Operations. In this newly created...
Dec 20, 2021 07:35 am ET
Life Sciences Companies Investor Presentations Now Available for On-Demand Viewing
Individual and institutional investors as well as advisors are invited to log-on to VirtualInvestorConferences.com to view presentations
Dec 20, 2021 07:35 am ET
Life Sciences Companies Investor Presentations Now Available for On-Demand Viewing
NEW YORK, Dec. 20, 2021 /PRNewswire/ -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the presentations from the December 16th Life Sciences Virtual Investor Conference are now available for on-demand viewing.
Dec 14, 2021 07:35 am ET
Virtual Conference for Life Sciences Companies Broadcast Live December 16th
Company executives will share corporate vision and answer audience questions at VirtualInvestorConferences.com
Dec 10, 2021 07:30 am ET
Thinking about buying stock in Energy Focus, C3Ai Inc, Vyne Therapeutics, American Virtual Cloud Technologies, or ReShape Lifesciences?
NEW YORK, Dec. 10, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for EFOI, AI, VYNE, AVCT, and RSLS.
Dec 09, 2021 11:19 am ET
Life Sciences Virtual Investor Conference: Company Executives Present Live December 16th
NEW YORK, Dec. 9, 2021 /PRNewswire/ -- Virtual Investor Conferences, the leading proprietary investor conference series, announced the agenda for its quarterly event for public and private companies, investors, and industry professionals from around the world. This day-long virtual event will showcase live company presentations and interactive discussions focused on the life sciences industry.
Dec 09, 2021 07:35 am ET
ReShape Lifesciences to Webcast Live at Life Sciences Investor Forum on December 16th
SAN CLEMENTE, Calif., Dec. 9, 2021 /PRNewswire/ -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that Bart Bandy, Chief Executive Officer and President and Tom Stankovich, Chief Financial Officer of ReShape Lifesciences, will present a company overview live at VirtualInvestorConferences.com, at 2:00 pm ET on December 16th.     
Nov 16, 2021 08:30 am ET
ReShape Lifesciences Witnesses Great Success with Direct-to-Consumer Marketing Campaign
ReShape Lifesciences Inc. (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health-solutions company, previously announced successful campaigns to help more consumers take control of their lives and their weight with a national...
Nov 11, 2021 08:30 am ET
ReShape Lifesciences Reports Third Quarter and Nine Month 2021 Financial and Operational Results
ReShape Lifesciences Inc. (NASDAQ: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today reported its financial and operational results for the three and nine months ended September 30, 2021. Recent Highlights...
Nov 08, 2021 08:30 am ET
ReShape Lifesciences to Report Third Quarter 2021 Financial and Operational Results on Thursday, November 11, 2021
ReShape Lifesciences Inc. (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health-solutions company, announced today that it will report its third quarter 2021 financial and operational results on Thursday, November 11, 2021 at...
Nov 04, 2021 08:30 am ET
ReShape Lifesciences™ to Launch Line of ProCare Health® Supplements to Meet Consumers’ Nutritional Needs
ReShape Lifesciences Inc. (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced the launch of an advanced line of supplements for bariatric surgery and medical weight loss patients, ReShape...
Oct 19, 2021 08:30 am ET
ReShape Lifesciences to Present at Dawson James 6th Annual Small Cap Growth Conference
ReShape Lifesciences Inc. (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health-solutions company, announced Thomas Stankovich, Chief Financial Officer of the Company, will present at the Annual Small Cap Growth Conference...
Oct 12, 2021 08:00 am ET
ReShape Launches National Advertising Campaign for Flagship Product, Lap-Band®
ReShape Lifesciences Inc. (NASDAQ: RSLS), the premier physician-led weight loss and metabolic health-solutions company, announced the launch of a multi-platform consumer advertising campaign utilizing national television, print, social media, and...
Sep 23, 2021 08:00 am ET
ReShape Lifesciences™ Featured in BioTuesdays
ReShape Lifesciences Inc. (NASDAQ:RSLS), the premier physician-led weight loss solutions company, today announced the company was highlighted in this week’s BioTuesdays feature article, titled “ReShape Lifesciences forging weight loss and metabolic...
Sep 13, 2021 08:00 am ET
ReShape Lifesciences™ to Host Exhibit at Bariatric Summit
ReShape Lifesciences Inc. (NASDAQ:RSLS), the premier physician-led weight loss solutions company, today announced the company will host an exhibit at the upcoming 17th Annual Bariatric Summit in Washington, D.C. September 18-19, 2021. ReShape...
Sep 09, 2021 08:30 am ET
ReShape Lifesciences™ to Present at Oppenheimer Fall Healthcare Life Sciences and Med Tech Summit on September 20, 2021
ReShape Lifesciences Inc. (NASDAQ: RSLS), the premier physician-led weight loss and metabolic health-solutions company, announced that its leadership will present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit on Monday,...
Aug 31, 2021 08:00 am ET
ReShape Lifesciences™ Appoints Al Diaz as Vice President of Operations and Research and Development
ReShape Lifesciences Inc. (NASDAQ:RSLS), the premier physician-led weight loss solutions company, today announced the appointment of Al Diaz as Vice President of Operations and Research and Development. Mr. Diaz will be responsible for overseeing...
Aug 19, 2021 10:35 am ET
Thinking about buying stock in Sonnet BioTherapeutics, Biocept, ReShape Lifesciences, Tencent Music Entertainment, or Cleveland-Cliffs?
NEW YORK, Aug. 19, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SONN, BIOC, RSLS, TME, and CLF.
Aug 16, 2021 08:00 am ET
Aug 05, 2021 08:00 am ET
ReShape Lifesciences Reports Preliminary Unaudited Second Quarter 2021 Financial Results and Provides Business Update
SAN CLEMENTE, CA / ACCESSWIRE / August 5, 2021 / ReShape Lifesciences Inc. (NASDAQ:RSLS), a leading developer and distributor of minimally invasive medical devices to treat obesity and metabolic diseases, today reported its preliminary unaudited financial and operational results for the three months ended June 30, 2021.
Aug 03, 2021 08:00 am ET
ReShape Lifesciences(TM) CEO Bart Bandy Featured on the Big Biz Show
SAN CLEMENTE, CA / ACCESSWIRE / August 3, 2021 / ReShape Lifesciences Inc. (NASDAQ:RSLS), the premier physician-led weight loss solutions company, today announced CEO Bart Bandy's featured interview on the Big Biz Show, a local-San Diego business talk show.
Jul 29, 2021 08:30 am ET
ReShape Lifesciences to Report Second Quarter 2021 Financial and Operational Results on Thursday, August 5, 2021
Webinar will be available discussing recent major milestones that same day
Jul 13, 2021 08:30 am ET
ReShape Lifesciences(TM) Launches Online Consumer Marketplace Offering Products Supporting Four Key Dimensions of Wellness: Nutrition, Exercise, Sleep and Stress
SAN CLEMENTE, CA / ACCESSWIRE / July 13, 2021 / ReShape Lifesciences Inc. (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced the launch of ReShape Marketplace ™ as an extension of reshape care ™, the company's reimbursed telehealth service for weight loss across any physician prescribed therapy. ReShape Marketplace provides consumers with a collection of creative, competitively priced, yet practical wellness products in the areas of nutrition, exercis
Jul 07, 2021 08:30 am ET
ReShape Lifesciences Moves Lap-Band Manufacturing to United States
SAN CLEMENTE, CA / ACCESSWIRE / July 7, 2021 / ReShape Lifesciences Inc. (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced it has completed their Lap-Band® manufacturing transition from Apollo Endosurgery, Inc to a Massachusetts-based manufacturer. ReShape Lifesciences™ expects this change to enable it to reduce costs, improve margins and directly control the manufacturing process.
Jul 01, 2021 08:30 am ET
ReShape Lifesciences Sees Lap-Band Growth as COVID-19 Pandemic Heightens Obesity Crisis
SAN CLEMENTE, CA / ACCESSWIRE / July 1, 2021 / ReShape Lifesciences Inc. (NASDAQ:RSLS), the premier physician-led weight-loss solutions company, today announced that Lap-Band® utilization has increased since COVID-19 in response to patients' increased desire for a reimbursed, effective, and sustainable weight-loss procedure that can be provided in outpatient surgery centers. The Lap-Band is clinically proven to be the safest bariatric procedure available on the market, backed by ov
Jun 30, 2021 08:30 am ET
ReShape Lifesciences Completes $46 Million Capital Raise With Key Institutional Shareholders
Funding provides for the acceleration of its internal growth strategy and the continued development of Reshape's weight-loss portfolio
Jun 29, 2021 09:27 am ET
ReShape Lifesciences Enters into Warrant Exercise Transaction for $46.2 Million in Gross Proceeds
SAN CLEMENTE, CA / ACCESSWIRE / June 29, 2021 / ReShape Lifesciences Inc. (NASDAQ:RSLS), a global weight-loss solutions leader, announced today that it has entered into a warrant exercise agreement with existing accredited investors to exercise certain outstanding warrants to purchase up to an aggregate of 7.9 million shares of the company's common stock. In consideration for the immediate exercise of the existing warrants for cash, the exercising holders received new unregistered warrants to purchase up to an aggregate of 5.9 million shares (equal to 75% of the shares of comm
Jun 28, 2021 10:55 am ET
Thinking about buying stock in SoFi Technologies, American Airlines, ReShape Lifesciences, Nokia, or Paysafe?
NEW YORK, June 28, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SOFI, AAL, RSLS, NOK, and PSFE.
Jun 17, 2021 08:45 am ET
ReShape Lifesciences Closes First Day of Trading on the NASDAQ Capital Market
Shares of ReShape Lifesciences commenced trading on The Nasdaq Capital Market at market open on June 16, 2021 under the ticker symbol "RSLS"
Jun 16, 2021 07:30 am ET
ReShape Lifesciences Completes Merger with Obalon Therapeutics
Shares of ReShape Lifesciences to commence trading on The Nasdaq Capital Market on June 16, 2021 under ticker symbol "RSLS"
Jun 15, 2021 12:05 pm ET
ReShape Lifesciences Inc. and Obalon Therapeutics, Inc. Announce Anticipated Closing of Merger
SAN CLEMENTE, CA and SAN DIEGO, CA / ACCESSWIRE / June 15, 2021 / ReShape Lifesciences Inc. (OTCQB:RSLS) and Obalon Therapeutics, Inc. (NASDAQ:OBLN) announced today the anticipated closing of their previously announced merger to be effective after the close of the market today, June 15, 2021. The shares of common stock of the combined company are expected to commence trading on The Nasdaq Capital Market on Wednesday, June 16, 2021, under the name ReShape Lifesciences Inc. and the trading symbol "RSLS."
Jun 08, 2021 07:30 am ET
ReShape Lifesciences Inc. and Obalon Therapeutics, Inc. Update on Status of Pending Merger
SAN CLEMENTE, CA and SAN DIEGO, CA / ACCESSWIRE / June 8, 2021 / ReShape Lifesciences Inc. (OTCQB:RSLS) and Obalon Therapeutics, Inc. (NASDAQ:OBLN) announced today that the parties anticipate the closing of their previously announced merger to occur promptly after approval of their pending Nasdaq listing application. While there can be no assurance that the listing application will be approved, Nasdaq approval is the sole remaining condition to closing in the merger agreement (other than conditions that the parties anticipate being satisfied at the closing). Upon the closing o
May 24, 2021 07:30 am ET
Reminder: Obalon Therapeutics Continues to Urge Stockholders to Vote FOR All Proposals Related to Merger with ReShape Lifesciences
SAN DIEGO, CA / ACCESSWIRE / May 24, 2021 / Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable gas-filled intragastric balloon system for the treatment of obesity, is taking this opportunity to remind its stockholders to vote on all the proposals related to the proposed merger with ReShape Lifesciences Inc. in advance of the upcoming reconvened special meeting of Obalon stockholders (the "Special Meeting") on May 25, 2021, at 8:30 a.m. PT.
May 21, 2021 07:30 am ET
Obalon Therapeutics Continues to Urge Stockholders to Vote FOR All Proposals Related to Merger with ReShape Lifesciences
SAN DIEGO, CA / ACCESSWIRE / May 21, 2021 / Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable gas-filled intragastric balloon system for the treatment of obesity, is taking this opportunity to remind its stockholders to vote on all the proposals related to the proposed merger with ReShape Lifesciences Inc. in advance of the upcoming reconvened special meeting of Obalon stockholders (the "Special Meeting") on May 25, 2021, at 8:30 a.m. PT.
May 18, 2021 07:30 am ET
Obalon Therapeutics Stockholders Special Meeting Adjourned to May 25, 2021
Urging all Shareholders to Vote For Proposals Related to Merger with ReShape LifeSciences Inc.
May 17, 2021 04:05 pm ET
ReShape Lifesciences Announces First Quarter 2021 Financial and Operational Results
SAN CLEMENTE, CA / ACCESSWIRE / May 17, 2021 / ReShape Lifesciences Inc. (OTCQB:RSLS), a leading developer and distributor of minimally invasive medical devices to treat obesity and metabolic diseases, today reported its financial and operational results for the three months ended March 31, 2021.
Mar 10, 2021 04:30 pm ET
ReShape Lifesciences Announces Fourth Quarter and Full Year 2020 Financial Results
SAN CLEMENTE, CA / ACCESSWIRE / March 10, 2021 / ReShape Lifesciences Inc. (OTCQB:RSLS), a global weight-loss solutions leader, today reported financial and operational results for the fourth quarter and full year ended December 31, 2020.
Mar 08, 2021 08:00 am ET
Jan 22, 2021 04:46 pm ET
OBALON ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of OBLN and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Obalon Therapeutics, Inc. (NASDAQ: OBLN) breached their fiduciary duties or violated the federal...
Jan 21, 2021 01:57 pm ET
SHAREHOLDER ALERT: WeissLaw LLP Investigates Obalon Therapeutics, Inc.
NEW YORK, Jan. 21, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Obalon Therapeutics, Inc. ("Obalon" or the "Company") (NASDAQ: OBLN) in connection with the proposed merger of the Company with ReShape Lifesciences Inc. ("ReShape") (OTCQB: RSLS).  Under the terms of the merger agreement, ReShape will acquire Obalon in an all-stock transaction, pursuant to which Obalon will be renamed ReShape Lifesciences Inc. and will trade under the NASDAQ ticker symbol "RSLS."  Upon completion of the merger, Re
Jan 20, 2021 08:45 am ET
ReShape Lifesciences Inc. to Merge With Obalon Therapeutics, Inc. to Expand Weight Loss Product Offering
SAN CLEMENTE, CA / ACCESSWIRE / January 20, 2021 / ReShape Lifesciences Inc. (OTCQB:RSLS), a global weight-loss solutions leader, announced today that it has entered into a definitive merger agreement with Obalon Therapeutics, Inc., which is listed on the NASDAQ Capital Market, a company focused on developing and commercializing novel technologies for weight loss, under which ReShape and Obalon will combine in an all-stock transaction.
Nov 12, 2020 04:30 pm ET
ReShape Lifesciences Announces Third Quarter 2020 Financial and Operational Results
SAN CLEMENTE, CA / ACCESSWIRE / November 12, 2020 / ReShape Lifesciences Inc. (OTCQB:RSLS), a global weight-loss solutions leader, today reported financial and operational results for the three months ended September 30, 2020.
Nov 10, 2020 08:00 am ET
ReShape Lifesciences to Report Third Quarter 2020 Financial and Operational Results on Thursday, November 12, 2020
SAN CLEMENTE, CA / ACCESSWIRE / November 10, 2020 / ReShape Lifesciences Inc. (OTCQB:RSLS), a leading developer and distributor of minimally invasive medical devices to treat obesity and metabolic diseases, announced today that it will report its third quarter 2020 financial and operational results on Thursday, November 12, 2020 after the close of the U.S. financial markets.
Aug 13, 2020 04:30 pm ET
ReShape Lifesciences Announces Second Quarter 2020 Financial and Operational Results
SAN CLEMENTE, CA / ACCESSWIRE / August 13, 2020 / ReShape Lifesciences Inc. (OTCQB:RSLS), a global weight-loss solutions leader, today reported financial and operational results for the three months ended June 30, 2020.
Aug 11, 2020 08:00 am ET
ReShape Lifesciences to Report Second Quarter 2020 Financial and Operational Results on Thursday, August 13, 2020
SAN CLEMENTE, CA / ACCESSWIRE / August 11, 2020 / ReShape Lifesciences Inc. (OTCQB:RSLS), a leading developer and distributor of minimally invasive medical devices to treat obesity and metabolic diseases, announced today that it will report its second quarter 2020 financial and operational results on Thursday, August 13, 2020 after the close of the U.S. financial markets.
Jul 21, 2020 08:00 am ET
ReShape Lifesciences Recognizes National Parents' Day Offering New Resources for Women Considering Weight-Loss and Parenthood
The minimally-invasive Lap-Band® Procedure is proven to improve fertility and support healthier pregnancies.
Jul 13, 2020 08:00 am ET
ReShape Lifesciences' Weight-Loss Portfolio Aligned with CDC's COVID-19 Updates
Individuals suffering from obesity with a Body Mass Index (BMI) of 30 or higher now identified for increased risk with COVID-19
Jun 22, 2020 08:00 am ET
May 14, 2020 04:05 pm ET
ReShape Lifesciences Announces First Quarter 2020 Financial and Operational Results
SAN CLEMENTE, CA / ACCESSWIRE / May 14, 2020 / ReShape Lifesciences Inc. (OTCQB:RSLS), a leading developer and distributor of minimally invasive medical devices to treat obesity and metabolic diseases, today reported financial and operational results for the three months ended March 31, 2020.
Mar 26, 2020 04:05 pm ET
ReShape Lifesciences Announces Fourth Quarter and Full Year 2019 Financial Results
SAN CLEMENTE, CA / ACCESSWIRE / March 26, 2020 / ReShape Lifesciences Inc. (OTCQB:RSLS), a leading developer and distributor of minimally invasive medical devices to treat obesity and metabolic diseases, today reported financial results for the three months and full year ended December 31, 2019.
Mar 23, 2020 08:00 am ET
ReShape Lifesciences to Host Fourth Quarter and Full Year 2019 Conference Call on March 26, 2020
SAN CLEMENTE, CA / ACCESSWIRE / March 23, 2020 / ReShape Lifesciences Inc. (OTCQB:RSLS), a leading developer and distributor of minimally invasive medical devices to treat obesity and metabolic diseases, today announced that it will host a conference call to discuss financial results for the fourth quarter and full year 2019 on Thursday, March 26, 2020 at 1:30 PM Pacific Time.
Nov 14, 2019 04:10 pm ET
ReShape Lifesciences Announces Third Quarter 2019 Financial Results
SAN CLEMENTE, CA / ACCESSWIRE / November 14, 2019 / ReShape Lifesciences Inc. (OTCQB:RSLS), a leading developer and distributor of minimally invasive medical devices to treat obesity and metabolic diseases, today reported financial results for the three months ended September 30, 2019.
Nov 11, 2019 12:50 pm ET
ReShape Lifesciences Announces 1-for-120 Reverse Stock Split
SAN CLEMENTE, CA / ACCESSWIRE / November 11, 2019 / ReShape Lifesciences Inc. (OTCQB:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced that its Board of Directors has declared a 1-for-120 reverse stock split of the company's common stock, which will be effective for trading purposes upon the commencement of trading on November 12, 2019. At that time, each 120 shares of issued and outstanding common stock and equivalents will be converted into one share of common stock. As a result of the reverse stock split, p
Nov 07, 2019 05:30 pm ET
ReShape Lifesciences to Host Third Quarter 2019 Conference Call on November 14, 2019
SAN CLEMENTE, CA / ACCESSWIRE / November 7, 2019 / ReShape Lifesciences Inc. (OTCQB:RSLS), a leading developer and distributor of minimally invasive medical devices to treat obesity and metabolic diseases, today announced that it will host a conference call to discuss financial results for the third quarter of 2019 on Thursday, November 14, 2019 at 1:30 PM Pacific Time.
Nov 05, 2019 08:00 am ET
ReShape Lifesciences Announces Strategic Marketing Partnership for LAP-BAND(R)
SAN CLEMENTE, CA / ACCESSWIRE / November 5, 2019 / ReShape Lifesciences Inc. (OTCQB:RSLS), a leading developer and distributor of minimally invasive medical devices to treat obesity and metabolic diseases, announced today that the company has signed a marketing agreement with Sequence Health, a leading patient engagement solutions company, with a goal to increase LAP-BAND® Procedures in the United States.
Oct 30, 2019 08:00 am ET
ReShape Lifesciences Appoints Thomas Stankovich as Chief Financial Officer
SAN CLEMENTE, CA / ACCESSWIRE / October 30, 2019 / ReShape Lifesciences Inc. (OTCQB:RSLS), a leading developer and distributor of minimally invasive medical devices to treat obesity and metabolic diseases, announced today the appointment of Thomas Stankovich as Chief Financial Officer (CFO) effective immediately.
Oct 17, 2019 08:00 am ET
ReShape Lifesciences Announces Attendance and Presentation at Obesity Week 2019
SAN CLEMENTE, CA / ACCESSWIRE / October 17, 2019 / ReShape Lifesciences Inc. (OTCQB:RSLS), a leading developer and distributor of minimally invasive medical devices to treat obesity and metabolic diseases, announced today that the company will be attending ObesityWeek 2019, taking place at the Mandalay Bay Resort in Las Vegas, Nevada, from November 3-7, 2019.
Sep 23, 2019 04:55 pm ET
ReShape Lifesciences Enters into Early Warrant Exercise Transaction and Receives an Additional $7.65 Million in Proceeds
SAN CLEMENTE, CA / ACCESSWIRE / September 23, 2019 / ReShape Lifesciences Inc. (OTCQB:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today entered into an early warrant exercise transaction with the holders of 400,000,000 Series B Warrants issued in ReShape's June 2019 private placement pursuant to a warrant exercise agreement. The early exercise of the warrants resulted in approximately $7.65 million of aggregate gross proceeds to ReShape. ReShape intends to use the net proceeds from the warrant exercise for general working capital
Sep 03, 2019 08:00 am ET
ReShape Lifesciences(TM) to Participate in the H. C. Wainwright Global Investment Conference
SAN CLEMENTE, CA / ACCESSWIRE / September 3, 2019 / ReShape Lifesciences Inc. (OTCQB:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today the company plans to participate in the upcoming H.C. Wainwright Global Investment Conference in New York, NY.
Aug 14, 2019 04:05 pm ET
ReShape Lifesciences Announces Second Quarter 2019 Financial Results
San Clemente, CA / ACCESSWIRE / August 14, 2019 / ReShape Lifesciences Inc. (OTCQB: RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today reported financial results for the three months ended June 30, 2019.
Aug 08, 2019 07:25 pm ET
ReShape Lifesciences to Host Second Quarter 2019 Conference Call on August 14, 2019
SAN CLEMENTE, CA / ACCESSWIRE / August 8, 2019 / ReShape Lifesciences Inc. (OTCQB:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced that it will host a conference call to discuss financial results for the second quarter of 2019 on Wednesday, August 14, 2019 at 1:30 PM Pacific Time.
Jun 18, 2019 08:00 am ET
ReShape Lifesciences to Highlight LAP-Band Weight Loss Technology at ASMBS Spring Meeting
SAN CLEMENTE, CA / ACCESSWIRE / June 18, 2019 / ReShape Lifesciences Inc. (OTCQB: RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today that the Company will be exhibiting its products and will have two presentations featuring the Company's proprietary LAP-BAND® technology at the American Society for Metabolic and Bariatric Surgery (ASMBS) Weekend 2019, taking place at the downtown Chicago Marriott from June 20-22, 2019.
Jun 14, 2019 07:00 am ET
ReShape Lifesciences Announces $8 Million Private Placement
SAN CLEMENTE, CA / ACCESSWIRE / June 14, 2019 / ReShape Lifesciences Inc. (OTCQB: RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced that it has entered into definitive agreements with certain healthcare focused institutional investors for the sale of 400,000,000 shares of common stock (or common stock equivalents), series A warrants to purchase up to 400,000,000 shares of common stock and series B warrants to purchase up to 400,000,000 shares of common stock in a private placement at a price of $0.02 per share and
Jun 04, 2019 08:00 am ET
ReShape Lifesciences Strengthens Executive Leadership Team with Appointment of Kevin Condrin as Senior Vice President of Commercial
SAN CLEMENTE, CA / ACCESSWIRE / June 4, 2019 / ReShape Lifesciences Inc. (OTCQB: RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today the appointment of Kevin Condrin as Senior Vice President, Commercial, effective immediately. In this role, Kevin will oversee global commercial activities for ReShape Lifesciences™ products in addition to coordinating all marketing, business development and field operations.
May 20, 2019 04:05 pm ET
ReShape Lifesciences Announces First Quarter 2019 Financial Results
SAN CLEMENTE, CA / ACCESSWIRE / May 20, 2019 / ReShape Lifesciences Inc. (OTCQB: RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today reported financial results for the three months ended March 31, 2019.
May 20, 2019 08:00 am ET
ReShape Lifesciences to Host First Quarter 2019 Conference Call on May 20, 2019
SAN CLEMENTE, CA / ACCESSWIRE / May 20, 2019 / ReShape Lifesciences Inc. (OTCQB: RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced that it will host a conference call to discuss financial results for the first quarter of 2019 on Monday, May 20, 2019 at 1:30 PM Pacific Time.
Apr 18, 2019 08:00 am ET
ReShape Lifesciences Announces Distribution in Australia
SAN CLEMENTE, CA / ACCESSWIRE / April 18, 2019 / ReShape Lifesciences Inc. (OTCQB: RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced that as of April 1, 2019, the company is selling its LAP-BAND® product in the Australian market through a relationship with Satori Healthcare. Satori Healthcare is a medical device distributor focused on the Australian bariatric market. The founder of Satori Healthcare has over 20 years of experience in the medical device industry, including 6 years of direct responsibilit
Apr 01, 2019 04:05 pm ET
ReShape Lifesciences Announces Fourth Quarter and Full Year 2018 Financial Results
SAN CLEMENTE, CA / ACCESSWIRE / April 1, 2019 / ReShape Lifesciences Inc. (NASDAQ: RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today reported financial results for the three months and year ended December 31, 2018.
Apr 01, 2019 08:00 am ET
ReShape Lifesciences Implants First Patient in ENDURE II Trial to Support CE Marking of ReShape Vest
SAN CLEMENTE, CA / ACCESSWIRE / April 1, 2019 / ReShape Lifesciences Inc. (OTCQB: RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today that the company has successfully implanted its first patient in the ENDURE II trial designed to support CE Marking of the ReShape VestTM.
Mar 29, 2019 08:00 am ET
ReShape Lifesciences Announces $2 Million Convertible Note Financing
SAN CLEMENTE, CA / ACCESSWIRE / March 29, 2019 / ReShape Lifesciences Inc. (OTCQB: RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced that it has entered into a definitive agreement with certain institutional investors for a $2 million convertible note financing, which notes will be issued in a private placement. The notes will mature three months after their issuance and, if not repaid, will then initially be convertible into shares of common stock at a conversion price equal to the lesser of $0.33 and 80% of the
Mar 26, 2019 08:00 am ET
ReShape Lifesciences Announces Appointment of Barton P. Bandy as President and Chief Executive Officer
SAN CLEMENTE, CA / ACCESSWIRE / March 26, 2019 / ReShape Lifesciences Inc. (OTCQB: RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today the appointment of Barton P. Bandy as President and Chief Executive Officer effective April 1, 2019. As previously announced, Dan W. Gladney will step down as President and Chief Executive Officer on March 31, 2019 and will continue to serve as Chairman of the Board for ReShape Lifesciences.
Mar 19, 2019 04:05 pm ET
ReShape Lifesciences to Host Fourth Quarter and Full Year 2018 Conference Call on April 1, 2019
SAN CLEMENTE, CA / ACCESSWIRE / March 19, 2019 / ReShape Lifesciences Inc. (OTCQB: RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced that it will host a conference call to discuss financial results for the fourth quarter and full year 2018 on Monday, April 1, 2019 at 1:30 PM Pacific Time.
Feb 25, 2019 08:00 am ET
ReShape Vest to be Showcased at 4th Annual Surgical Disruptive Technology Summit
SAN CLEMENTE, CA / ACCESSWIRE / February 25, 2019 / ReShape Lifesciences Inc. (OTCQB: RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today that the Company's ReShape VestTM will be discussed during a session at the 4th Annual Surgical Disruptive Technology Summit taking place at the JW Marriott Hotel in Houston, Texas from March 2-4, 2019.
Feb 19, 2019 08:00 am ET
ReShape Lifesciences to Debut LAP-BAND Technology at Minimally Invasive Surgery Symposium
SAN CLEMENTE, CA / ACCESSWIRE / February 19, 2019 / ReShape Lifesciences Inc. (OTC PINK: RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today that the Company will be exhibiting the LAP-BAND technology for the first time since its acquisition. The technology will be featured at the ReShape Lifesciences booth at the Minimally Invasive Surgery Symposium (MISS) taking place at the Encore at Wynn Las Vegas from February 25-28, 2019.
Jan 28, 2019 08:00 am ET
ReShape Lifesciences Announces Chief Executive Officer Departure
SAN CLEMENTE, CA / ACCESSWIRE / January 28, 2019 / ReShape Lifesciences Inc. (OTC Pink: RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced that Dan W. Gladney has decided to step down from his role as President and Chief Executive Officer of the company effective as of March 31, 2019. Mr. Gladney will continue to serve as Chairman of the Board. The ReShape Lifesciences Board of Directors will immediately begin to search for the company's next President and Chief Executive Officer.
Dec 18, 2018 08:00 am ET
Apollo Endosurgery, Inc. Announces the Sale of Its Surgical Product Line
Apollo Endosurgery, Inc. (“Apollo”) (Nasdaq:APEN), a global leader in less invasive medical devices for bariatric and gastrointestinal procedures, today announced the sale of its Surgical product line, which consists of the Lap-Band® adjustable gastric banding system and other accessories used in laparoscopic bariatric surgery, to ReShape Lifesciences Inc. (“ReShape”) (Nasdaq: RSLS). The definitive transaction agreements were signed and closed simultaneously yesterday, December 17, 2018.
Dec 18, 2018 08:00 am ET
ReShape Lifesciences Acquires Lap-Band System in Exchange for ReShape Balloon
Transaction Brings Broadly Reimbursed Product with MeaningfulRevenue to ReShape
Dec 06, 2018 06:00 am ET
ReShape Lifesciences Expands International Business in the Middle East
SAN CLEMENTE, CA / ACCESSWIRE / December 6, 2018 / ReShape Lifesciences Inc. (NASDAQ: RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced that the Company is further expanding their ReShape Balloon™ business in the Middle East via several recent developments:
Dec 03, 2018 08:00 am ET
ReShape Lifesciences Announces Live Surgery Course for ReShape Vest
SAN CLEMENTE, CA / ACCESSWIRE / December 3, 2018 / ReShape Lifesciences Inc. (NASDAQ: RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced that the Company will be holding a live-surgery surgical training for bariatric surgeons and key opinion leaders who will serve as investigators in the Company's ENDURE II trial in the European Union. The ENDURE II trial is designed to support CE Marking of the ReShape VestTM.
Nov 28, 2018 05:05 pm ET
ReShape Lifesciences Provides Financing and Corporate Update
Closing on Recent Financings Resulting in $25 Million in Gross Proceeds Company Funded to Support Current Operations Into 2020
Nov 26, 2018 01:00 pm ET
ReShape Lifesciences Announces $10 Million Registered Direct Offering
SAN CLEMENTE, CA / ACCESSWIRE / November 26, 2018 / ReShape Lifesciences Inc. (NASDAQ: RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced that it has entered into definitive agreements with two healthcare focused institutional investors for the purchase of 8,000,000 shares of its common stock and warrants to purchase 8,000,000 shares of its common stock, at a purchase price of $1.25 per share and associated warrants, for gross proceeds of approximately $10 million, in a registered direct offering. The closing of th
Nov 26, 2018 08:00 am ET
ReShape Lifesciences Presents New Data on Proprietary Technology for Type 2 Diabetes
SAN CLEMENTE, CA / ACCESSWIRE / November 26, 2018 / ReShape Lifesciences Inc. (NASDAQ: RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced new data that was presented during a poster presentation at the recent ObesityWeek 2018 conference in Nashville, Tennessee.
Nov 14, 2018 04:05 pm ET
Nov 12, 2018 08:00 am ET
ReShape Lifesciences Completes Investigator Meeting for ReShape Vest Clinical Trial in the European Union
SAN CLEMENTE, CA ACCESSWIRE / November 12, 2018 / ReShape Lifesciences Inc. (NASDAQ: RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today that on November 7, 2018 the company conducted an investigator meeting in conjunction with the trial in the European Union to support CE Marking of the ReShape Vest.TM The investigator meeting took place in Frankfurt, Germany and was intended to further establish relationships with the study team and to prepare investigators for the upcoming clinical trial for the ReShape Vest.
Nov 08, 2018 08:00 am ET
ReShape Lifesciences Announces National VA Contract for ReShape Balloon
"We are very pleased that surgeons at VA medical facilities now have the ability to treat veterans fighting obesity with the ReShape Balloon," said Dan Gladney, ReShape Lifesciences President and Chief Executive Officer. " There are over one million eligible veterans who are struggling with obesity and they, as well as all patients, deserve access to every option that may help them fight this disease.We look forward to working closely with the VA and Academy Medical to increase awareness and training so that the ReShape Balloon can be offered as soon as possible."
Nov 07, 2018 08:00 am ET
ReShape Lifesciences Announces 1-for-140 Reverse Stock Split
SAN CLEMENTE, CA / ACCESSWIRE / November 7, 2018 / ReShape Lifesciences Inc. (NASDAQ: RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced that its Board of Directors has declared a 1-for-140 reverse stock split of the company's common stock, which will be effective for trading purposes upon the commencement of trading on November 8, 2018. At that time, each 140 shares of issued and outstanding common stock and equivalents will be converted into one share of common stock. As a result of the reverse stock split, propo
Oct 31, 2018 08:00 am ET
ReShape Lifesciences to Host Third Quarter 2018 Conference Call on November 14, 2018
SAN CLEMENTE, CA / ACCESSWIRE / October 31, 2018 / ReShape Lifesciences Inc. (NASDAQ:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced that it will host a conference call to discuss financial results for the third quarter 2018 on Wednesday November 14, 2018 at 1:30 PM Pacific Time.
Oct 29, 2018 08:00 am ET
ReShape Lifesciences Announces Retirement of Series D Preferred Stock
SAN CLEMENTE, CA / ACCESSWIRE / October 29, 2018 / ReShape Lifesciences Inc. (NASDAQ: RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today that as of Friday, October 19, 2018, all shares of the Company's Series D Preferred Stock have been converted into ReShape Lifesciences common shares. A total of $6 million of shares of Series D Preferred Stock, which are now fully retired, were issued pursuant to a securities purchase agreement dated April 2, 2018. The Company used the net proceeds from this offering to continue
Oct 25, 2018 08:00 am ET
ReShape Lifesciences Announces Attendance and Presentation at ObesityWeek 2018
SAN CLEMENTE, CA / ACCESSWIRE / October 25, 2018 / ReShape Lifesciences Inc. (NASDAQ: RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today that the Company will be exhibiting its products and will be the subject of a poster presentation at ObesityWeek 2018, taking place at Music City Center in Nashville, Tennesee from November 11-15, 2018.
Oct 08, 2018 08:00 am ET
ReShape Lifesciences Announces Investigator Meeting for ReShape Vest Clinical Trial in European Union
SAN CLEMENTE, CA / ACCESSWIRE / October 8, 2018 / ReShape Lifesciences Inc. (NASDAQ: RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today that the company plans to conduct an investigator meeting in conjunction with the trial in the European Union to support CE Marking of the ReShape Vest.TM The meeting, which is planned for November 7, 2018, in Frankfurt, Germany, will focus on device training and review and will include discussion of the clinical protocol in anticipation of initiating study enrollment in the first
Oct 04, 2018 08:00 am ET
ReShape Lifesciences Presents New Data on Extension of Weight Loss with ReShape Patient Portal
SAN CLEMENTE, CA / ACCESSWIRE / October 4, 2018 / ReShape Lifesciences Inc. (NASDAQ: RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today that new data supporting increased weight loss related to use of the ReShape BalloonTM interactiave web portal was presented by Dr. Scott Shikora, MD, FACS; Professor of Surgery Harvard Medical School; Director, Center for Metabolic and Bariatric Surgery, Brigham and Women's Hospital, Boston, MA. Dr. Shikora shared the data last week during a poster presentation at the 23rd World C
Sep 24, 2018 08:00 am ET
ReShape Lifesciences Announces Acceptance of Abstract to be Presented at ObesityWeek 2018
SAN CLEMENTE, CA / ACCESSWIRE / September 24, 2018 / ReShape Lifesciences Inc. (NASDAQ: RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced that the company has had an abstract accepted by the scientific committee of The Obesity Society.
Sep 21, 2018 08:00 am ET
ReShape Lifesciences Announces Poster at IFSO Annual Conference
SAN CLEMENTE, CA / ACCESSWIRE / September 21, 2018 / ReShape Lifesciences Inc. (NASDAQ: RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today that the Company's technology will be the subject of a poster at the 23rd World Congress of the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO), taking place in Dubai, United Arab Emirates from September 26-29, 2018.
Sep 18, 2018 06:00 am ET
ReShape Lifesciences Announces Pricing of Public Offering
SAN CLEMENTE, CA / ACCESSWIRE / September 18, 2018 / ReShape Lifesciences Inc. (NASDAQ:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced the pricing of its previously announced public offering of 11,688,890 shares of its common stock and warrants to purchase up to 5,844,445 shares of its common stock, at a public offering price of $0.045 per share and associated warrant. The offering is expected to close on or about September 20, 2018, subject to the satisfaction of customary closing conditions. The gross proceeds
Sep 14, 2018 04:01 pm ET
ReShape Lifesciences Announces Proposed Public Offering
SAN CLEMENTE, CA / ACCESSWIRE / September 14, 2018 / ReShape Lifesciences Inc. (NASDAQ: RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced that it has commenced a public offering of shares of its common stock and warrants to purchase shares of its common stock. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. All of the securities in the proposed offering are to be sold by ReShape Lifes
Sep 06, 2018 08:00 am ET
ReShape Lifesciences Announces New Patent Grant Expanding its Gastric Vest Patent Portfolio
SAN CLEMENTE, CA / ACCESSWIRE / September 6, 2018 / ReShape Lifesciences Inc. (NASDAQ: RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today that The State Intellectual Property Office of The People's Republic of China has granted a device patent to the Company that expands the patent portfolio for the ReShape VestTM. The Chinese patent number ZL201410538627.2, which is titled ''Gastric Restriction Devices for Treating Obesity'' is directed to a novel laparoscopic gastric restriction device to treat obesity.
Aug 24, 2018 08:00 am ET
ReShape Lifesciences to Present at H.C. Wainwright 20th Annual Global Investment Conference
SAN CLEMENTE, CA / ACCESSWIRE / August 24, 2018 / ReShape Lifesciences Inc. (NASDAQ: RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced the company will be participating in the upcoming H.C. Wainwright 20th Annual Global Investment Conference taking place from September 4-6, 2018 at the St. Regis Hotel in New York, NY.
Aug 14, 2018 04:05 pm ET
ReShape Lifesciences Announces Second Quarter 2018 Financial Results
SAN CLEMENTE, CA / ACCESSWIRE / August 14, 2018 / ReShape Lifesciences Inc. (NASDAQ: RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today reported financial results for the three months ended June 30, 2018.
Aug 10, 2018 11:14 am ET
ReShape Lifesciences Announces Termination of Underwriting Agreement for Previously-Announced Public Offering
SAN CLEMENTE, CA / ACCESSWIRE / August 10, 2018 / ReShape Lifesciences Inc. (NASDAQ: RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today that the underwriting agreement for its underwritten public offering that priced on August 7, 2018 has been terminated by the company's underwriter for the offering in accordance with its terms due to Nasdaq's determination that the offering was not a public offering under the Nasdaq rules, and therefore could not be completed without shareholder approval. As a result of the termin
Aug 07, 2018 11:40 pm ET
ReShape Lifesciences Announces Pricing of Underwritten Public Offering of Common Stock
SAN CLEMENTE, CA / ACCESSWIRE / August 7, 2018 / ReShape Lifesciences Inc. (NASDAQ: RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced the pricing of its previously announced underwritten public offering of 12,514,412 shares of its common stock at a public offering price of $0.085 per share. The offering is expected to close on or about August 10, 2018, subject to the satisfaction of customary closing conditions.The gross proceeds from the offering, before deducting underwriting discounts and commissions and estima
Aug 07, 2018 04:01 pm ET
ReShape Lifesciences Announces Proposed Underwritten Public Offering of Common Stock
SAN CLEMENTE, CA / ACCESSWIRE / August 7, 2018 / ReShape Lifesciences Inc. (NASDAQ: RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced that it has commenced an underwritten public offering of shares of its common stock. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. All of the shares in the proposed offering are to be sold by ReShape Lifesciences.
Aug 03, 2018 08:00 am ET
ReShape Lifesciences to Host Second Quarter 2018 Conference Call on August 14, 2018
SAN CLEMENTE, CA / ACCESSWIRE / August 3, 2018 / ReShape Lifesciences Inc. (NASDAQ: RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced that it will host a conference call to discuss financial results for the second quarter 2018 on Tuesday, August 14, 2018 at 1:30 PM Pacific Time.
Aug 02, 2018 07:00 am ET
ReShape Lifesciences Announces Registered Direct Offering
SAN CLEMENTE, CA / ACCESSWIRE / August 2, 2018 / ReShape Lifesciences Inc. (NASDAQ: RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced that it has entered into definitive agreements with several institutional investors for the purchase of 1,000,000 shares of its common stock, at a purchase price per share of $0.60, for gross proceeds of approximately $0.6 million, in a registered direct offering. Additionally, ReShape Lifesciences has also agreed to issue to the investors unregistered warrants to purchase up to 1,0
Jul 31, 2018 08:00 am ET
ReShape Lifesciences Announces European Trial to Support CE-Mark of ReShape Vest
SAN CLEMENTE, Calif., July 31, 2018 /PRNewswire/ -- ReShape Lifesciences Inc. (NASDAQ:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today the Company has commenced site initiation training for the first clinical trial site that will participate in the multi-center trial of the ReShape VestTM to support CE Mark approval.
Jul 11, 2018 09:00 am ET
ReShape Lifesciences Announces $2.7 Million Registered Direct Offering Priced At-the-Market
SAN CLEMENTE, Calif., July 11, 2018 /PRNewswire/ -- ReShape Lifesciences Inc. (Nasdaq:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced that it has entered into definitive agreements with several institutional investors for the purchase of 1,241,382 shares of its common stock, at a purchase price per share of $2.05, for gross proceeds of approximately $2.55 million, in a registered direct offering priced at-the-market. Additionally, ReShape Lifesciences has also agreed to issue to the investors unregistered warrants to purchase
Jul 10, 2018 08:00 am ET
ReShape Lifesciences Expands Intra-gastric Balloon Business to Include Brigham and Women's Hospital in Boston
SAN CLEMENTE, Calif., July 10, 2018 /PRNewswire/ -- ReShape Lifesciences Inc. (NASDAQ:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today the successful implant of the first ReShape Balloon™ at the Brigham and Women's Hospital in Boston, MA.
Jun 27, 2018 08:00 am ET
ReShape Lifesciences Announces Acceptance of Abstract to be Presented at IFSO Annual Conference
SAN CLEMENTE, Calif., June 27, 2018 /PRNewswire/ -- ReShape Lifesciences Inc. (NASDAQ:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced that the company has had an abstract accepted by the scientific committee of the 23rd World Congress of the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO).
Jun 20, 2018 09:00 am ET
ReShape Lifesciences Announces $1.5 Million Registered Direct Offering Priced At-the-Market
SAN CLEMENTE, Calif., June 20, 2018 /PRNewswire/ -- ReShape Lifesciences Inc. (Nasdaq:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced that it has entered into definitive agreements with several institutional investors for the purchase of 469,490 shares of its common stock, at a purchase price per share of $3.07, for gross proceeds of approximately $1.44 million, in a registered direct offering priced at-the-market. Additionally, ReShape Lifesciences has also agreed to issue to the investors unregistered warrants to purchase up
Jun 19, 2018 08:00 am ET
ReShape Lifesciences Receives USPTO Issue Notification for Patent Covering its ReShape Vest
SAN CLEMENTE, Calif., June 19, 2018 /PRNewswire/ -- ReShape Lifesciences Inc. (NASDAQ:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announces that the United States Patent and Trademark Office ("USPTO") has issued an Issue Notification for U.S. Patent Number 10010441 entitled "Gastric Restriction Device for Treating Obesity," which covers a patent application regarding the Company's Gastric Vest System (the "ReShape VestTM"). Barring any unforeseen circumstances, this patent will be valid until December 5, 2028.
Jun 07, 2018 09:12 am ET
ReShape Lifesciences Announces $1.5 Million Registered Direct Offering Priced At-the-Market
SAN CLEMENTE, Calif., June 7, 2018 /PRNewswire/ -- ReShape Lifesciences Inc. (Nasdaq:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced that it has entered into definitive agreements with several institutional investors for the purchase of 374,572 shares of its common stock, at a purchase price per share of $3.92, for gross proceeds of approximately $1.47 million, in a registered direct offering priced at-the-market. Additionally, ReShape Lifesciences has also agreed to issue to the investors unregistered warrants to purchase up
Jun 06, 2018 08:00 am ET
ReShape Lifesciences Assembles World Class Scientific Advisory Board
SAN CLEMENTE, Calif., June 6, 2018 /PRNewswire/ -- ReShape Lifesciences Inc. (NASDAQ:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today the formation of the Company's Scientific Advisory Board (SAB), which includes the following five internationally recognized experts:
Jun 05, 2018 08:00 am ET
ReShape Lifesciences Announces New Patent Grant Expanding its Bioelectronic and Neuromodulation Portfolio
SAN CLEMENTE, Calif., June 5, 2018 /PRNewswire/ -- ReShape Lifesciences Inc. (NASDAQ:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today that the United States Patent and Trademark Office (USPTO) has granted a method and device patent to the Company that expands the ReShape Lifesciences™ neuromodulation intellectual property portfolio.  The U.S. patent number 9,668,778, which is titled "Neural Modulation Devices and Methods," is directed to a combination of blocking and stimulating the vagus and celiac nerve branches using specifi
Jun 01, 2018 02:32 pm ET
ReShape Lifesciences Announces 1-for-15 Reverse Stock Split
SAN CLEMENTE, Calif., June 1, 2018 /PRNewswire/ -- ReShape Lifesciences Inc. (NASDAQ: RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced that its Board of Directors has declared a 1-for-15 reverse stock split of the company's common stock, which will be effective for trading purposes upon the commencement of trading on June 4, 2018. At that time, each 15 shares of issued and outstanding common stock and equivalents will be converted into one share of common stock. As a result of the reverse stock split, proportional adjustme
May 24, 2018 08:00 am ET
ReShape Lifesciences to Participate at Digestive Disease Week 2018
SAN CLEMENTE, Calif., May 24, 2018 /PRNewswire/ -- ReShape Lifesciences Inc. (NASDAQ:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today that the company will be exhibiting and participating at Digestive Disease Week (DDW), which is taking place from June 2-5, 2018 at the Walter E. Washington Convention Center in Washington, DC.  
May 16, 2018 08:00 am ET
ReShape Lifesciences Trains Eleven Surgeons in Saudi Arabia
SAN CLEMENTE, Calif., May 16, 2018 /PRNewswire/ -- ReShape Lifesciences Inc. (NASDAQ:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today that the company and its distributor representatives recently trained eleven doctors in Saudi Arabia on its ReShape BalloonTM technology. 
May 14, 2018 04:04 pm ET
ReShape Lifesciences Announces Record Revenue for First Quarter 2018
SAN CLEMENTE, Calif., May 14, 2018 /PRNewswire/ -- ReShape Lifesciences Inc. (NASDAQ:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today reported financial results for the three months ended March 31, 2018.  
May 10, 2018 08:00 am ET
Investor Expectations to Drive Momentum within Plains Group Holdings, EnteroMedics, Vanda Pharmaceuticals, Cinemark, EPR Properties, and The Estee Lauder Companies — Discovering Underlying Factors of
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Plains Group Holdings, L.P. (NYSE:PAGP), EnteroMedics Inc. (NASDAQ:RSLS),...
May 10, 2018 08:00 am ET
ReShape Lifesciences Announces Submission for Approval of ReShape Balloon™ in Canada
SAN CLEMENTE, Calif., May 10, 2018 /PRNewswire/ -- ReShape Lifesciences Inc. (NASDAQ:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today the submission of an application to the Medical Devices Bureau of the Therapeutic Products Directorate in Canada that seeks to amend the Company's existing Canadian medical device license to include distribution of the Company's current generation ReShape Balloon™ and associated accessories. 
Apr 30, 2018 04:05 pm ET
ReShape Lifesciences to Host First Quarter 2018 Conference Call on May 14, 2018
SAN CLEMENTE, Calif., April 30, 2018 /PRNewswire/ -- ReShape Lifesciences Inc. (NASDAQ:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced that it will host a conference call to discuss financial results for the first quarter 2018 on Monday, May 14, 2018 at 1:30 PM Pacific Time.
Apr 24, 2018 08:00 am ET
ReShape Lifesciences Continues to Grow Presence in Middle East with Distribution in Bahrain
SAN CLEMENTE, Calif., April 24, 2018 /PRNewswire/ -- ReShape Lifesciences Inc. (NASDAQ:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today that the ReShape Balloon™ was granted registration by the National Health Regulation Authority (NHRA) in the Kingdom of Bahrain and the Company has signed a distribution agreement with Yousuf Mahmood Husain CO W.L.L. of Bahrain.  
Apr 18, 2018 08:30 am ET
Forty Surgeons Trained on ReShape Balloon at Hands-On Course During SAGES 2018
SAN CLEMENTE, Calif., April 18, 2018 /PRNewswire/ -- ReShape Lifesciences Inc. (NASDAQ:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today that over 40 surgeons were trained to implant the ReShape BalloonTM during the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) 2018 /16th World Congress that was held in Seattle from April 11-14, 2018.
Apr 10, 2018 08:30 am ET
ReShape Lifesciences Pioneers New Bio-electronic Technology for Treatment of Type 2 Diabetes
SAN CLEMENTE, Calif., April 10, 2018 /PRNewswire/ -- ReShape Lifesciences Inc. (NASDAQ:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today that the Company will be presenting early results of a new, novel use of the ReShape Lifesciences™ neuro-blocking technology in combination with separate-site vagus nerve stimulation for the treatment of type 2 diabetes.  Results of a recent study, which examines this first-ever application for the treatment of type 2 diabetes, will be discussed in a poster presentation during the Minnesota Neu
Apr 03, 2018 08:30 am ET
ReShape Lifesciences Continues Expansion in Middle East with Approval of ReShape Balloon in Saudi Arabia
SAN CLEMENTE, Calif., April 3, 2018 /PRNewswire/ -- ReShape Lifesciences Inc. (NASDAQ:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced approval of the Company's ReShape Balloon™ by the Kingdom of Saudi Arabia Saudi Food and Drug Authority. Congruent with this approval, the Company received an initial stocking order from Dar Al Zahrawi Medical Co LLC, KSA.
Apr 02, 2018 04:01 pm ET
ReShape Lifesciences Announces Fourth Quarter and Year End 2017 Financial Results
SAN CLEMENTE, Calif., April 2, 2018 /PRNewswire/ -- ReShape Lifesciences Inc. (NASDAQ:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today reported financial results for the three months and full year ended December 31, 2017.  
Apr 02, 2018 08:30 am ET
ReShape Lifesciences Announces $6 Million Registered Direct Offering
SAN CLEMENTE, Calif., April 2, 2018 /PRNewswire/ -- ReShape Lifesciences Inc. (NASDAQ:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced that it has entered into a securities purchase agreement with an institutional investor providing for the purchase and sale in a registered direct offering of shares of series D convertible preferred stock and a warrant to purchase shares of common stock for a purchase price of $6.0 million.
Mar 20, 2018 08:00 am ET
ReShape Lifesciences Announces Update on Integration Efforts and Reschedules Fourth Quarter and Full Year 2017 Conference Call to April 2, 2018
SAN CLEMENTE, Calif., March 20, 2018 /PRNewswire/ -- ReShape Lifesciences Inc. (NASDAQ:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced that it will be rescheduling its conference call to discuss financial results for the fourth quarter and full year 2017 to Monday, April 2, 2018 at 1:30 PM Pacific Time.
Mar 16, 2018 08:00 am ET
ReShape vBloc to be Featured at the Bariatric Metabolic Surgery Standardization World Consensus Meeting
SAN CLEMENTE, Calif., March 16, 2018 /PRNewswire/ -- ReShape Lifesciences Inc. (NASDAQ:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today that the ReShape vBloc™ product will be discussed during the Bariatric Metabolic Surgery Standardization World Consensus Meeting taking place in New Delhi, India from March 22-24, 2018.
Mar 09, 2018 08:00 am ET
Consolidated Research: 2018 Summary Expectations for Envision Healthcare, Taylor Morrison Home, Vertex Pharmaceuticals, ReShape Lifesciences Inc., American Axle & Manufacturing, and Lattice Semiconduc
NEW YORK, March 09, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Envision Healthcare Corporation (NYSE:EVHC), Taylor Morrison...
Mar 08, 2018 07:00 am ET
ReShape Lifesciences to Host Fourth Quarter and Full Year 2017 Conference Call on March 22, 2018
SAN CLEMENTE, Calif., March 8, 2018 /PRNewswire/ -- ReShape Lifesciences Inc. (NASDAQ:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced that it will host a conference call to discuss financial results for the fourth quarter and full year 2017 on Thursday, March 22, 2018 at 1:30 PM Pacific Time.
Mar 07, 2018 07:00 am ET
ReShape Lifesciences Announces Agreement with Academy Medical to Provide ReShape Balloon and ReShape vBloc to Department of Defense Facilities
SAN CLEMENTE, Calif., March 7, 2018 /PRNewswire/ -- ReShape Lifesciences Inc. (NASDAQ:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced an exclusive federal government business channel sales agreement with Academy Medical, LLC to sell its ReShape Balloon™ and ReShape vBloc™ products to U.S. Department of Defense (DoD) medical facilities.
Mar 05, 2018 07:00 am ET
ReShape LifeSciences Announces Real-World Safety and Efficacy Study Results on ReShape Balloon™ Published in Journal of Clinical Gastroenterology and Hepatology
SAN CLEMENTE, Calif., March 5, 2018 /PRNewswire/ -- ReShape Lifesciences Inc. (NASDAQ:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today that results from a study examining real-world safety and efficacy of the ReShape BalloonTM were published in the February issue of The Journal of Clinical Gastroenterology and Hepatology.
Feb 22, 2018 03:05 pm ET
ReShape Lifesciences Technologies to be Featured at Minimally Invasive Surgery Symposium
SAN CLEMENTE, Calif., Feb. 22, 2018 /PRNewswire/ -- ReShape Lifesciences Inc. (NASDAQ:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today that the Company and its products will be discussed during the Metabolic and Bariatric Sessions of the Minimally Invasive Surgery Symposium (MISS) taking place in Las Vegas from March 6-9, 2018.
Feb 01, 2018 06:00 am ET
ReShape Lifesciences Reports Preliminary Fourth Quarter and Full Year 2017 Revenue
SAN CLEMENTE, Calif., Feb. 1, 2018 /PRNewswire/ -- ReShape Lifesciences Inc. (NASDAQ:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today preliminary revenue results for the fourth quarter and year ended December 31, 2017.
Jan 25, 2018 07:00 am ET
ReShape Lifesciences Announces 2017 Weight Loss Contest Winner
SAN CLEMENTE, Calif., Jan. 25, 2018 /PRNewswire/ -- ReShape Lifesciences Inc. (NASDAQ:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced the winners of its 2017 weight loss contest, which recognizes patients for their successful weight loss with the ReShape BalloonTM. 
Dec 13, 2017 07:15 am ET
ReShape Lifesciences Announces Stocking Order from Medical Supplier in Dubai
SAN CLEMENTE, Calif., Dec. 13, 2017 /PRNewswire/ -- ReShape Lifesciences Inc. (NASDAQ:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases announced today that it has received a significant order for its ReShape® Integrated Dual Balloon System from Al Zahrawi Medical, a healthcare focused company specializing in medical, surgical, diagnostic and analytical lab and nuclear medicine supplies with presence throughout the United Arab Emirates (UAE) and Qatar.  This order, the second since Al Zawhari's initial stocking order in August 2017, is to suppor
Nov 15, 2017 07:40 am ET
New Research Coverage Highlights Synthetic Biologics, ReShape Lifesciences, Estée Lauder, Old Republic International, Vulcan Materials, and Taylor Morrison Home – Consolidated Revenues, Company Growth
NEW YORK, Nov. 15, 2017 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Synthetic Biologics, Inc. (NYSE:SYN), ReShape Lifesciences...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.